Henderson Jane
- SEC CIK
- 0001422304
In the past year, 12 open-market sale filings worth $2.09M and no purchases.
Current role at each company
- APGE Apogee Therapeutics, Inc.Chief Financial Officeras of Sep 3, 2026
- AKRO Akero Therapeutics, Inc.Directoras of Dec 9, 2025
- CRGX CARGO Therapeutics, Inc.Directoras of Aug 19, 2025
- ISEE IVERIC bio, Inc.Directoras of Jul 13, 2023
- IVVD Invivyd, Inc.Chief Financial Officeras of Feb 1, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $2.09M
- 12 filings
- Net
- −$2.09M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Henderson Jane as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
APGE Apogee Therapeutics, Inc.
Chief Financial Officer13 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 23, 2024 (view filing) | Aug 23 | Same day | Henderson JaneChief Financial Officer | SSale | −6.00K | $48.26 | −$289.6K | −2.9%200.9K after | |
| Nov 13, 2025 (view filing) | Nov 11 | 2 days | Henderson JaneChief Financial Officer | SSale | −1.00K | $60.00 | −$60.0K | −0.5%199.9K after | 10b5-1 |
| Nov 14, 2025 (view filing) | Nov 14 | Same day | Henderson JaneChief Financial Officer | SSale | −2.00K | $65.00 | −$130.0K | −1.0%197.9K after | 10b5-1 |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Henderson JaneChief Financial Officer | SSale | −1.50K | $70.00 | −$105.0K | −0.8%196.4K after | 10b5-1 |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Henderson JaneChief Financial Officer | SSale | −1.50K | $75.00 | −$112.5K | −0.8%194.9K after | 10b5-1 |
| Dec 23, 2025 (view filing) | Dec 19 | 4 days | Henderson JaneChief Financial Officer | SSale | −1.50K | $80.00 | −$120.0K | −0.8%193.4K after | 10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2-6 | 4 days | Henderson JaneChief Financial Officer | SSale | −8.00K | $76.14 | −$609.1K | −4.1%185.4K after | 3 lots10b5-1 |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $65.81 | −$131.6K | −1.1%183.4K after | 3 lots10b5-1 |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $70.22 | −$140.4K | −1.1%181.4K after | 4 lots10b5-1 |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $85.00 | −$170.0K | −1.1%179.4K after | 10b5-1 |
AKRO Akero Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 21, 2023 (view filing) | Jun 16 | 5 days | Henderson JaneDirector | SSale | −40.0K | $54.17 | −$2.17M | −100.0%0 after | 2 lots |
| Aug 12, 2025 (view filing) | Aug 12 | Same day | Henderson JaneDirector | SSale | −3.00K | $47.46 | −$142.4K | −24.2%9.40K after |